Seltorexant - Janssen Pharmaceuticals/Minerva Neurosciences

Drug Profile

Seltorexant - Janssen Pharmaceuticals/Minerva Neurosciences

Alternative Names: JNJ 7922; JNJ-42847922; MIN-202

Latest Information Update: 11 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Janssen Research & Development
  • Developer Janssen Research & Development; Minerva Neurosciences
  • Class Antidepressants; Ketones; Pyrimidines; Pyrroles; Sleep disorder therapies; Small molecules; Triazoles
  • Mechanism of Action Orexin receptor type 2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Insomnia; Major depressive disorder

Most Recent Events

  • 06 Dec 2017 Phase-II clinical trials in Insomnia in Japan (PO)
  • 06 Dec 2017 Minerva Neurosciences initiates enrolment in a phase IIb trial for Insomnia in European Union and the US
  • 11 Sep 2017 Janssen Research and Development completes a phase I trial in Healthy volunteers in USA (PO, Tablet) (NCT02837692)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top